8.2. imaging investigations patients, when?. sensitivity chest radiography us detection small rcc metastases poor. sensitivity chest radiography significantly lower ct-scans, proven comparative studies including histological evaluation [654-656]. therefore, follow-up recurrence detection chest radiography us less sensitive .positron-emission tomography pet-ct well bone scintigraphy used routinely rcc follow-up, due limited specificity sensitivity .surveillance also include evaluation renal function cardiovascular risk factors .outside scope regular follow-up imaging chest abdomen, targeted imaging considered patients organ-specific symptoms, e.g., ct mri imaging brain patients experiencing neurological symptoms . controversy exists optimal duration follow-up. authors argue follow-up imaging cost-effective five years; however, late metastases likely solitary justify aggressive therapy curative intent. addition, patients tumours develop contralateral kidney treated nss tumours detected early. several authors designed scoring systems nomograms quantify likelihood patients develop tumour recurrences, metastases, subsequent death . models, utilised summarised chapter 6 - prognosis, compared validated (le: 2). using prognostic variables, several stage-based follow-up regimens proposed, although, none propose follow-up strategies ablative therapies . post-operative nomogram available estimate likelihood freedom recurrence five years . recently, pre-operative prognostic model based age, symptoms tnm staging published validated (le: 3). follow-up algorithm monitoring patients treatment rcc needed, recognising patient’s risk recurrence profile, also efficacy treatment given (table 8.1). prognostic systems used adapt follow-up schedule according predicted risk recurrence. ancillary above, life-expectancy calculations based comorbidity age diagnosis may useful counselling patients duration follow-up . table 8.1: proposed follow-up schedule following treatment localised rcc, taking account patient risk recurrence profile treatment efficacy (based expert opinion ) risk profile (*)oncological follow-up date surgery3 mo6 mo12 mo18 mo24 mo30 mo36 mo> 3 yr (**) (***)> 5 yr (**) (***)low risk recurrencefor ccrcc:leibovich score 0-2for non-ccrcc:pt1a-t1b pnx-0 m0 histological grade 1 or2.-ct-ct-ct-ct every two yrs-intermediate risk recurrencefor ccrcc:leibovich score 3-5for non-ccrcc:pt1b pnx-0 and/or histological grade 3 4.-ctct-ct-ctct yrct onceeverytwo yrshigh risk recurrencefor ccrcc:leibovich score ≥ 6for non-ccrcc:pt2─pt4 histological gradeorpt any, pn1 cm0 histological gradectctctctct-ctct yrct onceeverytwo yrs ccrcc = clear cell renal cell carcinoma; ct = computed tomography; mo = months; non-ccrcc = non clear cell renal cell carcinoma; yr = years. table provides recommendations follow-up strategies low, intermediate high risk ofrecurrence patients curatively treated localised rcc either nss rn. computed tomography table refers imaging chest abdomen. alternatively, mri abdomen performedinstead ct-scan.* risk recurrence profiles based validated prognostic models. eau rcc guidelines panel recommends 2003 leibovich model ccrcc . however, validated models used physicians based national/regional recommendations. similar fashion, curatively treated localised non-ccrcc, panel recommends use university california los angeles integrated staging system (uiss) determine risk recurrence .** risk recurrence profiles, functional follow-up, mainly monitoring renal cardiovascular function, may continue according specific clinical needs irrespective length oncological follow-up.*** low-risk profiles > 3 years intermediate-risk > 5 years follow-up respectively, consider counselling patients terminating oncological follow-up imaging based assessment comorbidities, age, life expectancy and/or patient wishes.